期刊
BREAST
卷 24, 期 5, 页码 582-587出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.breast.2015.05.006
关键词
Breast Neoplasm; Nervous system diseases; Neuropathic pain; Polyneuropathies
资金
- Fundacao para a Ciencia e a Tecnologia [SFRH/BD/92630/2013]
- Grunenthal Foundation - Portugal
- Chair on Pain Medicine of the Faculty of Medicine, University of Porto
- Fundação para a Ciência e a Tecnologia [SFRH/BD/92630/2013] Funding Source: FCT
Objectives: Neurological complications secondary to breast cancer treatment may be an important contributor to these patients morbidity. We aimed to quantify the incidence of neurological complications of breast cancer treatment during the first year after diagnosis. Materials and methods: We performed a prospective cohort study with 506 patients recruited at the Portuguese Institute of Oncology of Porto, among those newly diagnosed. Participants underwent a neurological examination before treatment, after surgery, after chemotherapy (whenever applicable) and at one year after enrollment. The Montreal Cognitive Assessment was used to assess cognitive function, at baseline and at one year. We computed one-year cumulative incidence estimates and the corresponding 95% confidence intervals (95%CI) for each of the neurological complications. Results: Just over half of women had breast cancer stage 0 or I. A total of 6.9% were submitted to neoadjuvant chemotherapy but most of them completed adjuvant treatment - endocrine therapy, radiotherapy or chemotherapy (83.9%, 73.0% and 52.5%, respectively). The cumulative incidence of at least one oncological-related neurological complication during the first year after diagnosis was 48.4% (95%CI: 44.1 -52.8); the most frequent were neuropathic pain (30.8%, 95%CI: 27.0-35.0), chemotherapy-induced peripheral neuropathy (16.8%, 95%CI: 13.8-20.3), phantom breast pain/syndrome (16.6%, 95%CI: 13.6 -20.1) and cognitive decline (8.1%, 95%CI: 5.8-11.1). Conclusions: Neurological complications were a frequent side-effect of breast cancer management in the first year after diagnosis, especially neuropathic pain and chemotherapy-induced peripheral neuropathy. Accurate diagnosis and treatment of these complications are important to minimize the burden associated with breast cancer treatment in breast cancer survivors. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据